TOPLINE: Ustekinumab exhibited higher persistence rates as a second-line therapy than anti–tumour necrosis factor (anti-TNF) treatment in patients with Crohn’s disease. Clinical remission rates with ustekinumab improved progressively, reaching 100% by 5 years. METHODOLOGY: Researchers conducted this retrospective observational study of a prospective database to compare the persistence rates of ustekinumab as a second-line treatment ...
.png)
4990 Ash Street, Dallas, Texas 75207 972-815-7120
972-815-7120
admin@finhub.com
Copyright © 2024 finance. All Rights Reserved
